Directing action antiviral medicines
Long Term Agreement. Valid from Aug. 1 2019 until Dec. 31, 2020
1. Further price reductions are possible with the achievement of certain pooled volumes.
2. Some generic medicines may not be available in all countries due to patent or licensing restrictions.
3. Sofosbuvir and Daclatasvir available through the PAHO Strategic Fund are WHO prequalified generic products.
4. The reference prices are an average that will be in the following range: Daclatasvir 60mg Tablet 28 USD14.00 / 17.00 | Sofosbuvir 400mg Tablet28 USD18.00 / 25.00.
5. For budgeting purposes PAHO suggest Member States add an additional 15-25% to reflect the costs of shipping, insurance, 3% contribution to the SF capital account and the 1.25% PAHO administration fees.
6. Questions should be directed to email@example.com
For further information on the PAHO Strategic Fund please visit www.paho.org/strategicfund.